---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-24-000096"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:11:43.991887+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Labcorp Q2 revenue $3.22B (+6.2%), adj EPS $3.94; raises revenue guidance, boosts buyback $1B

## Summary
- Q2 revenue $3.22B (+6.2% YoY); diluted EPS $2.43 vs $1.74; adjusted EPS $3.94 vs $3.42.
- Free cash flow $432.9M vs $58.2M a year ago.
- Updated FY 2024 guidance: revenue growth 6.4%-7.5% (prior 4.8%-6.4%); adj EPS $14.30-$14.90 (incl. ~$0.40 Invitae dilution).
- Board approved $1.0B increase in share repurchase authorization to $1.4B; quarterly dividend $0.72/share.
- Invitae acquisition expected close early August; launched FDA-approved hemophilia B CDx and preeclampsia screening.

## SEC filing metadata
- accession: 0000920148-24-000096
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014824000096/0000920148-24-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014824000096/lh-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-24-000096
- JSON: https://secwatch.observer/filing/0000920148-24-000096.json
- Plain text: https://secwatch.observer/filing/0000920148-24-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.